摘要
目的:研究骨质疏松患者行血清胰岛素样生长因子结合蛋白3(IGFBP-3)、血清N端骨钙素(N-MID)、25羟基维生素D[25(OH)D]、骨密度(BMD)检测的效果。方法:数据取自本院2021年4月-2022年5月收治的80例骨质疏松患者,均行IGFBP-3、N-MID及25(OH)D检测,分析检测结果。结果:实验组患者的IGFBP-3、25(OH)D及N-MID、BMD水平均低于参照组患者相应指标水平(P<0.05);实验组患者IGFBP-3、25(OH)D及N-MID、BMD变化水平相互为正相关关系(P<0.05);采用多元回归分析显示影响BMD的主要因素中,IGFBP-3、25(OH)D、N-MID均为骨质疏松保护因素。结论:骨质疏松患者行IGFBP-3、25(OH)D及N-MID检测可切实观察病情、为疾病治疗提供参考数据,利于改善预后、效果显著。
Objective:To study the serum insulin-like growth factor-binding protein 3(IGFBP-3),serum N-terminal osteocalcin(N-MID),25-hydroxyvitamin D(25(OH)D),bone mineral density in osteoporosis patients(BMD)detection effect.Methods:Data were collected from 80 patients with osteoporosis who were admitted to our hospital from April 2021 to May 2022.Results:The levels of IGFBP-3,25(OH)D,N-MID,and BMD in the research group were lower than those in the reference group(P<0.05).25(OH)D,N-MID,and BMD levels were positively correlated with each other(P<0.05).Multiple regression analysis showed that among the main factors affecting BMD,IGFBP-3,25(OH)D and N-MID are both protective factors for osteoporosis.Conclusion:The detection of IGFBP-3,25(OH)D and N-MID in patients with osteoporosis can effectively observe the disease and provide reference data for disease treatment,which is beneficial to improve the prognosis and has a significant effect.
作者
张力
申鸿
郭洁
雷珂
安哲
崔张珂
李林
ZHANG Li;SHEN Hong;GUO Jie;LEI Ke;AN Zhe;CUI Zhang-ke;LI Lin(Department of clinical lab,The Third Affiliated Hospital of Xi'an Medical College,Xian,Shaanxi,710068,China;Department of clinical lab,Xian Jiaotong University Hospital,Xian,Shaanxi,710061,China;Department of clinical lab,The Second Affliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi,710004,China;Department of clinical lab,Shaanxi Cancer Hospital,Xi'an,Shaanxi,710068,China)
出处
《现代生物医学进展》
CAS
2023年第5期914-917,926,共5页
Progress in Modern Biomedicine
基金
陕西省重点研发计划项目(2020SF-170)。